Trial Profile
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Hydroxychloroquine (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Apr 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.